PDCD1
ENSG00000188389
Target class
Surface antigen
Chromosome
2
Approved drugs
7
Clinical candidates (approved and in development)
26
- Approved drugs
- 7
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 26
- Chemical probe available
- No
- Target name
- PDCD1
- Gene name
- Programmed cell death 1
- Gene symbol
- PDCD1
- Previous gene symbols
- SLEB2
- Protein name
- Programmed cell death protein 1 (Protein PD-1) (hPD-1) (CD antigen CD279)
- CD279
- PD1
- hSLE1
- PD-1
- Gene biotype
- Protein coding
- Gene family
- CD molecules|V-set domain containing
- Target class
- Surface antigen
- Target type
- Human gene
- Tissues expressed in
- 16
- Highest tissue expression
- 23.65
- Tissue specificity (Gini)
- 0.693
- Tissue specificity (tau)
- 0.953
- KEGG gene identifiers
- hsa:5133
- Protein interaction confidence
- 0.826688
- Protein interaction partners
- 64
- R-HSA-389948
- R-HSA-9679191
- R-HSA-9931295
- End position
- 241858894
- Start position
- 241849884
- Chromosome
- 2
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein.
- PubMed 30487606
- PubMed 31754127
- Tissue specificity (tau)
- 0.952722
- Expression inequality (Gini)
- 0.693396
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 23.65
- Spleen
- 11.89
- Heart - Atrial Appendage
- 5.14
- Small Intestine - Terminal Ileum
- 4.1
- Lung
- 3.25
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes23.65
- Spleen11.89
- Heart - Atrial Appendage5.14
- Small Intestine - Terminal Ileum4.1
- Lung3.25
- Whole Blood3.02
- Pituitary2.75
- Thyroid2.21
- Adipose - Visceral (Omentum)1.82
- Minor Salivary Gland1.62
- Prostate1.26
- Stomach1.24
- Fallopian Tube1.24
- Cervix - Endocervix1.22
- Vagina1.19
- Bladder1.05
- Esophagus - Mucosa0.99
- Adipose - Subcutaneous0.99
- Nerve - Tibial0.96
- Colon - Transverse0.95
- Kidney - Medulla0.9
- Artery - Coronary0.89
- Heart - Left Ventricle0.8
- Breast - Mammary Tissue0.79
- Uterus0.76
And 29 more, listed on the interactive page.
- GO:0002841
- GO:0006915
- GO:0006959
- GO:0050728
- GO:0050860
- GO:0050868
Cellular components
- GO:0005886
- GO:0004888
- GO:0005515
- GO:0038023
Related records
Trials (7,750)
- - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- 11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
- 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
- 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer
- 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
- 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
- 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
- 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
- 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
- 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
- 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression
- 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer
- 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
- 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
- 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
- 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
- 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
- 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Drugs (26)
- APL-501 Programmed cell death protein 1 inhibitor
- Balstilimab Programmed cell death protein 1 antagonist
- Budigalimab Programmed cell death protein 1 inhibitor
- Cadonilimab Programmed cell death protein 1 inhibitor
- Camrelizumab Programmed cell death protein 1 antagonist
- Cemiplimab Programmed cell death protein 1 inhibitor
- Cetrelimab Programmed cell death protein 1 inhibitor
- CS-1003 Programmed cell death protein 1 inhibitor
- Dostarlimab Programmed cell death protein 1 antagonist
- Finotonlimab Programmed cell death protein 1 inhibitor
- Lomvastomig Programmed cell death protein 1 inhibitor
- Nivolumab Programmed cell death protein 1 inhibitor
- Pembrolizumab Programmed cell death protein 1 inhibitor
- Penpulimab Programmed cell death protein 1 inhibitor
- Pidilizumab Programmed cell death protein 1 inhibitor
- Pimivalimab Programmed cell death protein 1 inhibitor
- Pucotenlimab Programmed cell death protein 1 inhibitor
- Retifanlimab Programmed cell death protein 1 antagonist
- Sasanlimab Programmed cell death protein 1 antagonist
- Serplulimab Programmed cell death protein 1 antagonist